Immunovant remains a high-risk, high-reward play, hinging on the success of its next-gen candidate IMVT-1402. Click to read my latest analysis of IMVT stock.

A 56-year-old man was admitted to the hospital because of left lower abdominal pain and anemia. He had a 1-year history of ...

IgE, best known for mediating allergic reactions, may also shape cancer outcomes. Learn how this immune molecule could serve as both a biomarker and a basis for next-generation therapies.

THE final countdown to the 2025 Inter-Guiana Games (IGG) begins this week as high-level sporting delegations from French Guiana and Suriname arrive in ...

Investing.com -- Jefferies in a note dated Wednesday has initiated coverage on Hansa Biopharma AB with a “buy” rating and a price target of SEK 100, citing momentum from its first-in-class ...

The third quarter 2025 financial results and business update will be discussed during a conference call and webcast presentation today at 1:30 pm CET/8:30 am ET. A webcast of the live call and replay ...

Hansa Biopharma AB, "Hansa" today announced that it will host a virtual event featuring two distinguished transplant surgeons; Professor Robert Montgomery from NYU Langone Transplant Institute and ...

The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG ...

Banks in emerging markets are increasingly providing non-financial services to their SME clients, typically consisting of ...

VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activityFinal ADAPT SC+ results show ...

Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation. First clinical data supports imlifidase ability ...